Stanford Researchers Restore Insulin Production in Mice Using Dual Cell Transplant

Scientists at Stanford Medicine have demonstrated that combining two types of donor cells—blood-forming stem cells and pancreatic islet cells—can halt the autoimmune destruction that defines Type 1 diabetes. In their mouse study, published November 18 in the Journal of Clinical Investigation, the transplant approach either completely prevented diabetes or fully reversed it in animals that already had the disease.

Type 1 diabetes occurs when the immune system mistakenly attacks and destroys the insulin-producing islet cells in the pancreas. This new strategy aims to replace those lost cells while simultaneously retraining the immune system to stop attacking them.

Throughout the six-month observation period, none of the transplanted mice developed graft-versus-host disease (GVHD), a serious condition in which immune cells from the donor attack the recipient's healthy tissue. This is a significant safety milestone, as GVHD has been a major obstacle in previous transplant approaches.

After receiving the transplants, the mice no longer required insulin injections or immunosuppressive medications—drugs that typically suppress the entire immune system. More importantly, the animals' original immune system stopped attacking the transplanted islet cells, suggesting the therapy actually helped restore immune tolerance rather than simply bypassing the problem.

The Stanford approach works by establishing what researchers call a 'hybrid immune system'—one containing cells from both the donor and the recipient. This balance appears critical to the therapy's success, allowing the transplanted cells to function without triggering rejection or autoimmune complications.

According to Seung K. Kim, MD, PhD, senior author and director of the Stanford Diabetes Research Center, the key steps used in this study are already being employed in human medicine for other conditions. This existing clinical experience could accelerate the pathway to testing this approach in people with Type 1 diabetes.

While these results are promising, the work remains in the preclinical stage. The findings were demonstrated in mice, and significant additional research and clinical trials would be necessary before this approach could be offered to patients.

Researchers believe the strategy could eventually benefit not only people with Type 1 diabetes, but also those with other autoimmune diseases and people requiring solid organ transplants. The potential to apply already-established clinical techniques offers a realistic foundation for moving toward human studies, though the timeline and specific next steps remain to be determined.

Origin: sciencedaily.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.